Pulmonary Arterial Hypertension (PAH) Market 2022 Key Drivers and Restraints, Regional Outlook, End-User Applicants by 2028

Pulmonary Arterial Hypertension (PAH) Market Outlook 2028
• The global pulmonary arterial hypertension (PAH) market was valued at US$ 5.2 Bn in 2020
• It is estimated to expand at a CAGR of 5.4% from 2021 to 2028
• The global pulmonary arterial hypertension (PAH) market is expected to reach the value of US$ 13.5 Bn by the end of 2028
Analysts' Viewpoint on Pulmonary Arterial Hypertension (PAH) Market Scenario
Research and development in the drug discovery platforms and collaborative efforts of healthcare professionals & governments to introduce drugs are driving the global pulmonary arterial hypertension (PAH) market amid the coronavirus pandemic. Companies in the global pulmonary arterial hypertension (PAH) market are accelerating their product development and leveraging revenue opportunities to gain edge over competitors. Market stakeholders are extending their services arms to gain competitive edge. Market contributors in the global pulmonary arterial hypertension (PAH) market should focus on effective and cost-efficient treatments for the patients. However, lack of awareness about the treatment and detection of PAH is expected to hamper the growth of the global pulmonary arterial hypertension (PAH) market during the forecast period.

Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

Increase in Awareness about Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when pulmonary arteries become narrow in diameter or get blocked. In the past few years, there has been an increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. There are high-growth opportunities for market players in the near future due to increasing prevalence of PAH across the globe.
Various treatments are available in the market that helps in controlling and slowing down the growth of the diseases and improving the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the global market. Moreover, favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1181

Rapid Growth in Geriatric Population to Fuel Market Expansion
The increase in geriatric population in developing countries is expected to drive the global pulmonary arterial hypertension market in the upcoming years. The rising incidence of PAH in the geriatric population is driving the global pulmonary arterial hypertension market during the forecast period. Aging is one of the non-modifiable factors that increases the risk related to PAH. Elderly people are more susceptible to this disease due to diastolic dysfunction and age-associated blood vessel stiffening. Several educational programs have been initiated by key market contributors and governments to increase awareness about PAH among healthcare providers and patients. All these factors are expected to boost the global pulmonary arterial hypertension market over the next few years.
Technological Advancements and Approval of New Drugs to Drive Global Market
Technological advancements in drug discovery & development, along with rising research & development activities across the globe are driving the pulmonary arterial hypertension (PAH) market. Based on drug class, the global pulmonary arterial hypertension (PAH) market has been classified into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate the market in the near future due to high demand. The SGC simulators segment is anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1181

Promising Drug Pipeline to Boost Market in North America
Geographically, North America is projected to dominate the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is followed by Europe, and the market in both regions is projected to grow remarkably throughout the forecast period. This can be ascribed to the availability of commercialization of new PAH drugs coupled with a promising drug pipeline. In addition, growing awareness among people in both regions about the rising availability of treatment for pulmonary arterial hypertension is also pushing the market growth.
Moreover, Asia Pacific possess lucrative opportunities for the market players. Countries such as Japan, New Zealand, Australia, China, and India are projected to offer high growth opportunities attributing to growing penetration of global players.
Pulmonary Arterial Hypertension (PAH) Market: Overview
• According to Transparency Market Research's latest report on the global pulmonary arterial hypertension (PAH) market for the historical period 2017-2019 and forecast period 2021-2028, increase in initiatives by key players, higher cases of pulmonary arterial hypertension, rise in adoption rate, availability of reimbursement, and entry of generics are projected to drive the global market during the forecast period.
Increase in Collaborations for Development of Novel Products: Key Driver
• Focus on collaborations & mergers by leading players to develop innovative products is anticipated to boost the growth of the global market during the forecast period. In 2017, Bayer AG and Vectura Group plc extended their collaboration to develop an upgraded version of nebulizer Breelib that improves the efficacy of iloprost aerosol therapy for pulmonary atrial hypertension. According to the National Institutes of Health, the nebulizer is still in clinical trial and the study was finished in March 2020.
• In September 2018, United Therapeutics entered into a collaboration with MannKind Corporation for the development and commercialization of dry powder formulation of treprostinil. This research was conducted by Mannkind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1181

COVID-19 Impact Analysis
• The impact of the coronavirus outbreak on the industry peaked during early 2020, wherein pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus crisis
• Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain had impeded the industry expansion
• The pandemic has reinforced the importance of pulmonary arterial hypertension drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.
Side Effects Associated with PAH Drugs: Key Restraint
• Side effects associated with PAH drugs are likely to hamper the growth of the global market. Vasodilators are primarily prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels.
• According to studies, vasodilators have a number of side effects including edema, heart palpitations, tachycardia, and chest pain. Due to the substantial side effects associated with the use of vasodilators among chronically ill patients, the U.S. FDA regulates the use of this drug.
• Moreover, manufacturers of PAH drugs that treat high blood pressure and dilate blood vessels are required to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercialization.
• The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the usage of PAH drugs are projected to restrain the global market during the forecast period.
Pulmonary Arterial Hypertension (PAH) Market: Competition Landscape
• This report profiles major players in the global pulmonary arterial hypertension (PAH) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
• The global pulmonary arterial hypertension (PAH) market is highly fragmented, with the presence of a number of international as well as regional players
• Leading players operating in the global pulmonary arterial hypertension (PAH) market are
o Actelion Pharmaceuticals, Ltd.
o Gilead Sciences, Inc.
o GlaxoSmithKline plc
o Pfizer, Inc.
o United Therapeutics Corporation, among others

Trending Reports:
https://www.transparencymarketresearch.com/trichomoniasis-drugs-market.html

https://www.transparencymarketresearch.com/squamous-non-small-cell-lung-cancer-market.html

Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.